News Bayer's regorafenib kicks off brain cancer platform trial Bayer has become the first pharma company to take part in a new platform trial designed to find new treatments for brain cancer.
News BMS’ Opdivo fails late-stage brain cancer test Bristol-Myers Squibb has run into yet another hurdle trying to extend the use of its immuno-oncology blockbuster Opdivo into new types of cancer.
Views & Analysis An echo through brain cancer’s empty pipeline Brain tumours kill more people aged under 40 than any other cancer, yet there have been no new treatments for more than a decade. What’s more, there are still none in the pipeline.
News Certain brain tumours could respond to immunotherapy Some brain tumours may respond to immunotherapy after all, according to a new study.
Views & Analysis Kick-starting innovation in Glioblastoma Can risk-sharing and real-world evidence can provide traction in treating the brain cancer Glioblastoma?
News Head patch device Optune improves brain cancer survival Median overall survival improved from 15 months to 21 months when combined with chemotherapy.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
